Rocket Pharmaceuticals (RCKT) Net Cash Flow (2014 - 2026)

Rocket Pharmaceuticals has reported Net Cash Flow for 13 years, with the latest figure at -$27.9 million in Q1 2026.

• Quarterly Net Cash Flow rose 75.45% year-over-year to -$27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$221000.0 (down 101.52% YoY) and the FY2025 annual result came in at -$86.1 million, down 179.93% from the prior year.
• Net Cash Flow slipped to -$27.9 million in Q1 2026 per RCKT's latest filing, from $1.6 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $180.6 million in Q3 2023 and troughed at -$169.8 million in Q4 2023.
• A 5-year average of -$10.8 million and a median of -$17.0 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow jumped 1877.56% in 2023, then sank 610.0% in 2025.
• Over 5 years, Net Cash Flow stood at -$56.2 million in 2022, then plunged by 202.23% to -$169.8 million in 2023, then surged by 157.75% to $98.0 million in 2024, then slumped by 98.38% to $1.6 million in 2025, then sank by 1863.22% to -$27.9 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$27.9 million, $1.6 million, and $43.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.